Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Recursion Pharmaceuticals Inc’s current trading price is -55.50% away from its 52-week high, while its distance from the 52-week low is 45.11%. The stock’s price range during this period has varied between $3.79 and $12.36. The company, active in the Healthcare sector, saw a trading volume of around 9.93 million for the day, considerably lower average daily volume of 27.8 million observed over the last three months.
Recursion Pharmaceuticals Inc (RXRX) currently has a stock price of $5.5. The stock saw a sharp increase in the last trading session, hitting a high of $10.0 after opening at $5.54. The lowest recorded price for the day was $3.0 before it closed at $5.77.
Recursion Pharmaceuticals Inc’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $12.36 on 02/18/25, and the lowest price during the same period was recorded at $3.79 on 04/09/25.
How Financial Performance Impacts Market Capitalization
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly rise of 20.61% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.39B.
Decoding Analysts’ Ratings for Recursion Pharmaceuticals Inc
As of right now, 1 analyst is rating Recursion Pharmaceuticals Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.20, with a change in price of -0.95. Similarly, Recursion Pharmaceuticals Inc recorded 25,457,039 in trading volume during the last 100 days, posting a change of -14.60%.
How RXRX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.07.
RXRX Stock Stochastic Average
As of today, the raw stochastic average of Recursion Pharmaceuticals Inc over the past 50 days is 35.64%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 19.40%. Additionally, the Stochastic %K and %D values for the company were 23.73% and 23.07%, respectively, over the past 20 days.
RXRX Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -12.43%.However, over the last six months, we can see a stronger performance of -47.77%. Over the last 30 days, the price of RXRX has leaped by -5.83%. And in the last five days, it has surged by 3.96%.
